152 related articles for article (PubMed ID: 17374991)
1. Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.
Bianchi F; Tagliabue E; Ménard S; Campiglio M
Cell Cycle; 2007 Mar; 6(6):643-6. PubMed ID: 17374991
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
3. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
4. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
5. Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas.
Kowara R; Salnikow K; Diwan BA; Bare RM; Waalkes MP; Kasprzak KS
Mol Cell Biochem; 2004 Jan; 255(1-2):195-202. PubMed ID: 14971660
[TBL] [Abstract][Full Text] [Related]
6. FHIT
Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
[TBL] [Abstract][Full Text] [Related]
7. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
8. Loss of Msh2 is not associated with FHIT deletion in breast carcinomas.
Yang Q; Nakamura Y; Nakamura M; Yoshimura G; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
Anticancer Res; 2002; 22(5):2591-5. PubMed ID: 12529969
[TBL] [Abstract][Full Text] [Related]
9. Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.
Bianchi F; Sasso M; Turdo F; Beretta GL; Casalini P; Ghirelli C; Sfondrini L; Ménard S; Tagliabue E; Campiglio M
J Cell Physiol; 2015 Nov; 230(11):2661-70. PubMed ID: 25711523
[TBL] [Abstract][Full Text] [Related]
10. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity in the fragile histidine triad (FHIT) locus and expression analysis of FHIT protein in patients with breast disorders.
Rabelo RA; Antunes LM; Etchebehere RM; Nomelini RS; Nascentes GA; Murta EF; Pedrosa AL
Clin Exp Obstet Gynecol; 2013; 40(1):89-94. PubMed ID: 23724516
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
13. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
14. Fhit and Wwox loss-associated genome instability: A genome caretaker one-two punch.
Schrock MS; Karras JR; Guggenbiller MJ; Druck T; Batar B; Huebner K
Adv Biol Regul; 2017 Jan; 63():167-176. PubMed ID: 27773744
[TBL] [Abstract][Full Text] [Related]
15. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
17. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
18. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis.
Kitamura A; Yashima K; Okamoto E; Andachi H; Hosoda A; Kishimoto Y; Shiota G; Ito H; Kaibara N; Kawasaki H
Oncology; 2001; 61(3):205-11. PubMed ID: 11574776
[TBL] [Abstract][Full Text] [Related]
19. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
20. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
